Patients with metastatic RCC were randomly assigned to pazopanib 800 mg per day for 10 weeks , a 2-week washout , and then sunitinib 50 mg per day ( 4 weeks on , 2 weeks off , 4 weeks on ) for 10 weeks , or the reverse sequence .